Author: Barr Paul Fisher Richard Friedberg Jonathan
Publisher: Informa Healthcare
ISSN: 0735-7907
Source: Cancer Investigation, Vol.25, Iss.8, 2007-11, pp. : 766-775
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Bortezomib is the first of the proteasome inhibitors to be used clinically. Among the various cancers susceptible to proteasome inhibition are the non-Hodgkin's lymphomas. Mantle cell lymphoma appears to be particularly sensitive, leading to the FDA approval of bortezomib in patients who have received at least one prior therapy. This demonstration of clinical efficacy has led to an explosion of research attempting to further understand the anti-tumor effect of proteasome inhibition and clinical investigations exploring bortezomib in combination with other agents. In this review, we will detail the clinical results and ongoing trials utilizing bortezomib in Hodgkin's and non-Hodgkin's lymphoma.
Related content
Bortezomib in mantle cell lymphoma
Future Oncology, Vol. 4, Iss. 2, 2008-04 ,pp. :
Bortezomib in the Treatment of Cancer
Recent Patents on Anti-Cancer Drug Discovery, Vol. 1, Iss. 3, 2006-11 ,pp. :
Role of radiotherapy in the treatment of primary mediastinal large Bcell lymphoma
Oncology Letters, Vol. 10, Iss. 5, 2015-01 ,pp. :